NYHA Class IV Approval: In August 2024, scPharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted approval for FUROSCIX, expanding the indication to include New York Heart ...

Meanwhile a 2018 study showed evidence “that short term memory and intelligence/reasoning may be improved by creatine ...

Creatine is considered safe for healthy people, but it might not be the right choice for everyone. For example, it might ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 20 ...

Detailed price information for Satellos Bioscience Inc (MSCL-T) from The Globe and Mail including charting and trades.

FDA approval of MIPLYFFATM and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra ...

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and EuropeCompleted ZYNQUISTA™ FDA ...

FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencelFDA also confirmed in ...

Various forms of technology nowadays can zero-in on sleep cycles, stress levels, heart rate spikes and even lactate ...

Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

This study identified nonpregnant adults with at least one outpatient encounter and serum creatinine assessment, focusing on ...

The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton ...